Lineage Therap (LCTX) Stock Statistics & Valuation Metrics

Lineage Therap has a market cap or net worth of $185.08M. The enterprise value is $191.20M.

Lineage Therap has 228,356,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lineage Therap’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -21.18%.

The current PE Ratio of Lineage Therap is -5.41. Lineage Therap’s PEG ratio is 0.25.

In the last 12 months, Lineage Therap had revenue of 9.50M and earned -18.61M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was -22.20M and capital expenditures -327.00K, giving a free cash flow of -22.52M billion.

Lineage Therap pays an annual dividend of $0.112, resulting in a dividend yield of ―

Lineage Therap upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Lineage Therap as a current ratio of 3.65, with Debt / Equity ratio of 5.31%

In the past 12 months, Lineage Therap has paid 27.00K in taxes.

Lineage Therap EV to EBITDA ratio is -2.75, with an EV/FCF ratio of -2.42.

Lineage Therap has $47.91M in cash and marketable securities with $2.24M in debt, giving a net cash position of -$45.66M billion.

Gross margin is 95.05%, with operating margin of -226.11%, and net profit margin of -195.90%.

The average price target for Lineage Therap is $4.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy